Bausch+Lomb Results Presentation Deck
Dry Eye Disease Requires Different Treatment Options
DED is a Growing Condition that is
Currently Underdiagnosed¹
50%
7%
Estimated US population
that has DED
-38M
BAUSCH + LOMB
Diagnosed DED
~19M
Current Patients on DED Rx
~1.4M
~96% of the estimated U.S. population
with DED is not treated with an Rx product
1. US Census, Decision Resource Group Dry Eye Disease Landscape & Forecast report published in December 2020.
2. The closing of the acquisition remains subject to receipt of regulatory approval and other customary closing conditions.
Tear Evaporation
Inflammation
Associated with
Dry Eye
Miebo
Miobo.
Miebo:
perlancane
botanic surn
For Topical
Opathime Use
STERILE
(lifitegrast
ophthalmic solution)5%
*Bausch+Lomb
announced intent to
acquire XIIDRAⓇ
from Novartis on
June 30, 2023²
16View entire presentation